Navigation Links
Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders

CHICAGO, Aug. 13 /PRNewswire-FirstCall/ -- As biotechnology, pharmaceutical and medical device companies increasingly move clinical trials beyond their own borders to other parts of the world, such as Asia, Eastern Europe and South America, complicated regulatory environments challenge those firms' efforts to do business, according to an analysis by Aon Corporation (NYSE: AOC). Aon's 2008 Clinical Trials Risk Map provides those companies a visual representation of the complex insurance requirements and risk management needs that exist for companies conducting clinical trials internationally.


A robust research and development pipeline is essential to bringing new drugs or medical products to market, with clinical trials being an important step in the process of regulatory approval and marketing. While companies find benefits to conducting trials abroad, insurance and risk management requirements vary. Missteps in the placement of insurance can delay or disrupt clinical trials, resulting in costly financial implications for the life sciences company.

In 53 percent of the countries included in Aon's analysis, businesses must include a certificate of insurance in their regulatory filing package. Additionally:

-- Certificates issued by locally licensed insurance companies are generally required for regulatory filings, and most countries' regulatory authorities have specific requirements for insurance certifications.

-- Turnaround time for certification issuance is often longer, particularly when local admitted insurance companies must be used.

-- Delays or errors in certification can result in delays in regulatory filings and approvals by ethics committees, ministries of health and other oversight authorities.

"Our analysis provides an overview of the constantly changing clinical trials landscape," said James Walters, managing director of Aon Risk Services' Life Sciences practice group. "Conducting clinical trials globally is an increasingly popular practice for firms seeking to bring better medicines and therapies to market, and insurance is the last thing that should stand in the way of the life sciences research so critical to human health and disease management."

To enable companies to better monitor clinical trials worldwide, Aon has developed a new Clinical Trials module as part of its risk management information system, RiskConsole. To date, companies used paper-based processes and spreadsheets to track clinical trials and coordinate coverage. RiskConsole offers a Web-based platform to manage the clinical trials process and ensure necessary insurance is secured.

Aon's report found that China, Estonia, Russia, Peru and Malaysia have been experiencing the most growth in the number of clinical trial sites. In China alone, the number of clinical trials grew by 47 percent in 2006.(1) And with the exception of Peru, each of these countries requires locally admitted insurance. Russia has a limited local market for clinical trials insurance, which presents an even greater challenge to the life sciences company seeking to expand their clinical trials into this country.

About the 2008 Clinical Trials Risk Map

Aon identified and plotted the regulatory risks of 71 countries on the 2008 Clinical Trials Risk Map. The insurance requirement in each country was noted as:

-- Green - "No CT Requirements" (no specific regulatory or ethics committee requirements);

-- Yellow - "CT Requirements" (specific regulatory or ethics committee requirements); or

-- Orange - "CT Requirements with Successor Liability Requirements" (specific regulatory requirements also require coverage for a period of time following the conclusion of the trial).

Produced by Aon Risk Services' Life Sciences practice group and the Aon Global Client Network, the map drew its information from a survey of the Aon Global Client Network in 71 countries to determine the regulatory and ethics committee requirements for Clinical Trial insurance. This information is housed in a proprietary database that is updated as regulations change.

To request a copy of the map, visit:

About Aon Corporation

Aon Corporation (NYSE: AOC) is the leading global provider of risk management services, insurance and reinsurance brokerage, human capital and management consulting. Through its 36,000 colleagues worldwide, Aon readily delivers distinctive client value via innovative and effective risk management and workforce productivity solutions. Our industry-leading global resources, technical expertise and industry knowledge are delivered locally through more than 500 offices in more than 120 countries. Aon was named the world's best broker by Euromoney magazine's 2008 Insurance Survey. In 2008, Aon ranked highest on the Business Insurance ranking of the world's largest insurance brokers based on commercial retail, wholesale, reinsurance and personal lines brokerage revenues. Aon also was ranked by A.M. Best as the number one insurance broker based on brokerage revenues in 2007 and 2008, and was voted best insurance intermediary, best reinsurance intermediary, and best employee benefits consulting firm in 2007 by the readers of Business Insurance. For more information on Aon, log onto

Media contacts:

Elly Krumwiede Rahsaan Johnson

312.729.4258 312.381.2684

(1) Berndt, E.R., Sinskeyy, A.J., Theirs, F.A. Trends in Globalization of

Clinical Trials. Nature Reviews: Drug Discovery [online]. November


SOURCE Aon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Franklin & Seidelmann Publishes Complex Podiatry MRI Study
2. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
3. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
4. Wound Management Technologies, Inc. Announces Agreement for Evidence Based Study for Diabetic Venous Ulcers
5. New Data Demonstrates 5-FU Personalized Chemotherapy Management (PCM(R)) Assay Provides Similar Performance to More Complicated Liquid Chromatography-Mass Spectrometry (LC-MS/MS)
6. Saladax Biomedicals 5-FU Personalized Chemotherapy Management (PCM(R)) Assay CE Marked for Distribution in the EU
7. Wound Management Technologies, Inc. Announces Evidence Based Study
8. University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients
9. Studies Point to Benefits of Personalized Chemotherapy Dose Management in Colorectal Cancer
10. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
11. Micromet Announces Changes in Management Team
Post Your Comments:
(Date:12/1/2015)... India , December 1, 2015 ... market research report "Immunotherapy Drugs Market by Type of Drug ... Checkpoint Inhibitors), Epidemiology, Regulatory and Pipeline Analysis - Global Forecast ... is poised to reach USD 73,529.2 Million by 2020 from ... from 2015 to 2020. Browse 37 ...
(Date:12/1/2015)... , 1 de diciembre de 2015 /PRNewswire/ ... para cuchillas de precisión, develó hoy un ... identidad de marca. El nuevo logo destaca ... y la ingeniería de productos con cuchillas ... ...
(Date:12/1/2015)... 2015 During the recent 2015 Transcatheter ... Francisco, CA , Medinol Ltd. continued to ... During a satellite symposium, "The BioNIR eDES: The ... Restenosis", a renowned physician panel discussed the key ... Coronary Stent System and the Medinol eDES Coronary ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... ... has been selected as a finalist in this year’s Fierce Innovation Awards: Healthcare ... IT Healthcare was recognized as a finalist in the category of Digital Solutions ...
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator of aesthetic and ... to the devices for sale in the United States. Clarity is a Superior ... nm Nd:YAG lasers, into a single platform that is easy to own and operate. ...
(Date:12/1/2015)... ... 01, 2015 , ... PYA’s latest white paper, “ PYA ... main “pain point” for merging or aligning healthcare provider organizations—when mergers and other ... This quick-read guidance suggests that failing to recognize the power of an ...
(Date:12/1/2015)... ... 2015 , ... PartnerTech , a leader in high-tech ... 2008. Gary Bruce, President of PartnerTech North America, currently serves as Director for ... of time in Sweden since joining PartnerTech based in Malmo, Sweden. He has ...
(Date:12/1/2015)... ... December 01, 2015 , ... Nurotron Biotechnology Co., Ltd., maker of ... to date. , The order will be from the China Disabled Persons’ Federation, ... System is an effective solution for children and adults suffering from severe and ...
Breaking Medicine News(10 mins):